{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:17:25Z","timestamp":1777598245420,"version":"3.51.4"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T00:00:00Z","timestamp":1498348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T00:00:00Z","timestamp":1498348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Dermatol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1111\/ced.13173","type":"journal-article","created":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T03:38:40Z","timestamp":1498448320000},"page":"735-742","source":"Crossref","is-referenced-by-count":37,"title":["Long-term management of chronic spontaneous urticaria with omalizumab"],"prefix":"10.1093","volume":"42","author":[{"given":"M.","family":"Pinto Gouveia","sequence":"first","affiliation":[{"name":"Dermatology Department; Coimbra University Hospital Centre; Coimbra Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gameiro","sequence":"additional","affiliation":[{"name":"Dermatology Department; Coimbra University Hospital Centre; Coimbra Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pinho","sequence":"additional","affiliation":[{"name":"Dermatology Department; Coimbra University Hospital Centre; Coimbra Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gon\u00e7alo","sequence":"additional","affiliation":[{"name":"Dermatology Department; Coimbra University Hospital Centre; Coimbra Portugal"},{"name":"Clinic of Dermatology; Faculty of Medicine; University of Coimbra; Coimbra Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,6,25]]},"reference":[{"key":"10.1111\/ced.13173-BIB0001|ced13173-cit-0001","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2222.2007.02678.x","article-title":"BSACI guidelines for the management of chronic urticaria and angio-oedema","volume":"37","author":"Powell","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1111\/ced.13173-BIB0002|ced13173-cit-0002","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","article-title":"The EAACI\/GA(2) LEN\/EDF\/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update","volume":"69","author":"Zuberbier","year":"2014","journal-title":"Allergy"},{"key":"10.1111\/ced.13173-BIB0003|ced13173-cit-0003","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2009.11.047","article-title":"The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria","volume":"125","author":"Staevska","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/ced.13173-BIB0004|ced13173-cit-0004","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1111\/ced.13173-BIB0005|ced13173-cit-0005","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/ced.13173-BIB0006|ced13173-cit-0006","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/ced.13173-BIB0007|ced13173-cit-0007","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdermsci.2013.08.011","article-title":"Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis","volume":"73","author":"Metz","year":"2014","journal-title":"J Dermatol Sci"},{"key":"10.1111\/ced.13173-BIB0008|ced13173-cit-0008","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.anai.2013.12.005","article-title":"Real-life experiences with omalizumab for the treatment of chronic urticaria","volume":"112","author":"Sussman","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1111\/ced.13173-BIB0009|ced13173-cit-0009","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jaad.2012.10.026","article-title":"Effective treatment of idiopathic chronic cold urticaria with omalizumab: report of 3 cases","volume":"69","author":"Moing","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/ced.13173-BIB0010|ced13173-cit-0010","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jaci.2013.10.015","article-title":"An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized","volume":"133","author":"Uysal","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/ced.13173-BIB0011|ced13173-cit-0011","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1517\/14712598.2013.822484","article-title":"Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice","volume":"13","author":"Labrador-Horrillo","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1111\/ced.13173-BIB0012|ced13173-cit-0012","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaad.2015.11.021","article-title":"Omalizumab in patients with severe and refractory solar urticaria: A phase II multicentric study","volume":"74","author":"Aubin","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/ced.13173-BIB0013|ced13173-cit-0013","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.aller.2013.11.007","article-title":"Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria","volume":"43","author":"Silva","year":"2015","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1111\/ced.13173-BIB0014|ced13173-cit-0014","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaci.2014.04.036","article-title":"The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria","volume":"135","author":"Chang","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/ced.13173-BIB0015|ced13173-cit-0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13223-015-0088-7","article-title":"Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care","volume":"11","author":"Savic","year":"2015","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1111\/ced.13173-BIB0016|ced13173-cit-0016","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jaad.2015.12.052","article-title":"The effect of omalizumab dosing and frequency in chronic idiopathic urticaria: Retrospective chart review","volume":"74","author":"Clark","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/ced.13173-BIB0017|ced13173-cit-0017","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000444985","article-title":"Omalizumab in chronic spontaneous urticaria: a Brazilian real-life experience","volume":"169","author":"Ensina","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"issue":"Suppl 5","key":"10.1111\/ced.13173-BIB0018|ced13173-cit-0018","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/jdv.13697","article-title":"Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria","volume":"30","author":"Gimenez-Arnau","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fced.13173","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ced.13173\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:44:56Z","timestamp":1676385896000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/42\/7\/735\/6621863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,25]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,10]]}},"URL":"https:\/\/doi.org\/10.1111\/ced.13173","archive":["Portico"],"relation":{},"ISSN":["0307-6938"],"issn-type":[{"value":"0307-6938","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6,25]]}}}